FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.